Over a three-year period, each investigator will receive up to $750,000 for a total of $10 million awarded for SU2C Innovative Research Grants. It is the hope that ideas for new SU2C Dream Teams will emerge from these Innovative Research Grants.
Watch the 2011 Innovative Research Grants recipients talk about their work and its potential impact on the treatment of people with cancer:
The 13 SU2C Innovative Research Grant recipients in 2011 are:
Targeting MLL in Acute Myeloid Leukemia
Yali Dou, PhD, is an associate professor in the department of pathology and holds a joint appointment in the department of biological chemistry at the University of Michigan.
Targeting Genetic and Metabolic Networks in T-ALL
Adolfo A. Ferrando, MD, PhD, is director of the Lymphoid Development and Malignancies Program, Herbert Irving Comprehensive Cancer Center, associate professor of pediatrics and pathology at Columbia University.
Targeting Protein Quality Control for Cancer Therapy
Estela Jacinto, PhD, is associate professor in the department of physiology and biophysics at the University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School.
Targeting PP2A and the Glutamine-Sensing Pathway as Cancer Treatment
Mei Kong, PhD, is assistant professor in the division of tumor cell biology at Beckman Research Institute of City of Hope in Duarte, California.
Chimeric RNAs Generated by Trans-splicing and Their Implications in Cancer
Hui Li, PhD, is assistant professor of pathology at the University of Virginia in Charlottesville, Virginia.
Exome Sequencing of Melanomas with Acquired Resistance to BRAF Inhibitors
Roger S. Lo, MD, PhD, is assistant professor in the division of dermatology/department of medicine and the department of molecular and medical pharmacology at the David Geffen School of Medicine at the University of California.
Identification and Targeting of Novel Rearrangements in High-risk ALL
Charles G. Mullighan, MD, is associate member in the department of pathology at St. Jude Children’s Research Hospital.
A Systems Approach to Understanding Tumor Specific Drug Response
Dana Pe’er, PhD, is associate professor in the biological sciences department at Columbia University in New York.
Targeting Sleeping Cancer Cells
Sridhar Ramaswamy, MD, is associate professor of medicine at Harvard Medical School and Massachusetts General Hospital Cancer Center, and associate member of the Broad Institute, and a principal member of the Harvard Stem Cell Institute.
Inhibiting Innate Resistance to Chemotherapy in Lung Cancer Stem Cells
Eric Alejandro Sweet-Cordero, MD, is assistant professor of pediatrics at Stanford University School of Medicine.
Developing New Therapeutic Strategies for Soft-tissue Sarcoma
Amy J. Wagers, PhD, is associate professor in the department of stem cell and regenerative biology at Harvard University and Harvard Medical School, and is a Howard Hughes Medical Institute early-career scientist.
Framing Therapeutic Opportunities in Tumor-activated Gametogenic Programs
Angelique W. Whitehurst, PhD, is assistant professor of pharmacology at the Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center.
Coupled Genetic and Functional Dissection of Chronic Lymphocytic Leukemia
Catherine J. Wu, MD, is assistant professor of medicine at Harvard Medical School and Dana-Farber Cancer Institute. She is staff physician at Brigham and Women’s Hospital and Dana-Farber Cancer Institute.
Updated: May 13, 2014